AVEFF (Avecho Biotechnology) ROE % Adjusted to Book Value : -41.06% (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Avecho Biotechnology ROE % Adjusted to Book Value?

Avecho Biotechnology's ROE % for the quarter that ended in Dec. 2024 was -49.27%. Avecho Biotechnology's PB Ratio for the quarter that ended in Dec. 2024 was 1.20. Avecho Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -41.06%.

Avecho Biotechnology ROE % Adjusted to Book Value Historical Data

The historical data trend for Avecho Biotechnology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology ROE % Adjusted to Book Value Chart

Avecho Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-15.04

-37.28

-12.95

-389.65

-51.98

Avecho Biotechnology Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-19.37	-52.49	-305.10	-27.24	-41.06

Competitive Comparison of Avecho Biotechnology's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Avecho Biotechnology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avecho Biotechnology's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's ROE % Adjusted to Book Value falls into.

Avecho Biotechnology ROE % Adjusted to Book Value Calculation

Avecho Biotechnology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-62.37%	/	1.20
	=	-51.98%

Avecho Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-49.27%	/	1.20
	=	-41.06%

Avecho Biotechnology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Avecho Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (OTCPK:AVEFF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

OEZ:Germany AVE:Australia

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Headlines

From GuruFocus

Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia

By PRNewswire • 03-03-2025